A woman I know, a friend I've had dinner with more times than I can count, sent me a panicked text after her first compounded GLP-1 dose.
A friend had referred her to a telehealth platform, raving about the results she'd seen from taking compounded semaglutide. Unlike brand-name medications, these formulations are prepared by licensed pharmacies and are not subject to the same FDA approval process as manufacturer-produced versions.
"This is the one I use," the friend wrote. "Super easy. You just fill out a form [to get it]."
The form asked how much weight she wanted to lose and how fast. The subsequent telehealth visit lasted minutes, and she wasn't sure whether the person reviewing her answers was a physician, a nurse, a physician assistant, or something else entirely. Her medical history went largely unexamined. A custom-mixed semaglutide arrived in the mail a few days later with a vial, a syringe, and a set of instructions she did her best to follow.
Within a day of her first dose, she was frantically texting me and calling poison control.
She was in her mid-40s and in perimenopause; overnight, her clothes had stopped fitting the way they used to. Her body was operating on a new set of terms she couldn't seem to negotiate. She just wanted to feel comfortable in her own skin again. She didn't really know the difference between the FDA-approved version, which is manufactured under strict regulatory oversight, and the pharmacy-created version, which is not. She knew Ozempic. She knew Wegovy. She had seen enough before-and-after posts to want the weight loss others found. When she discovered the branded formulas cost over a thousand dollars a month and required a prescription her insurance wouldn't cover, the telehealth platform offering their semaglutide blend at a fraction of the price felt less like a shortcut and more like the only door open to her. Everyone she knew seemed to be on some variant, and they all seemed fine.
She didn't think she was taking a risk. She thought she was doing what GLP-1 ads said to do: taking care of herself. Within a day of her first dose, she was frantically texting me and calling poison control.
I'm a gynecologist and a menopause specialist, and I've watched this story play out in my exam room with increasing frequency. I also live in the same world as my patients and friends. I'm a woman in midlife who has received the same messages about what my body should look like at this age, how I should manage its changes, and what it means to let it change at all. I know the pull of a solution that arrives via a friend's text and, later, in a box conveniently on your doorstep. What I also know, from the other side of the exam table, is what happens when that answer comes without medical oversight.
The weight loss industry tends to find medicine before the medicine finds its safeguards.
GLP-1s are genuinely effective. The weight loss data is real. The cardiovascular benefits are real. For the right patient, with proper medical supervision and a careful titration schedule, they represent a meaningful clinical advance, and I say that as someone who has watched them change lives. But the way these compounded versions of the medication are being marketed has been seen before and has never been stopped in time.
The weight-loss industry tends to find medicine before the medicine finds its safeguards. Ephedrine supplements flooded shelves in the 1990s, marketed as natural thermogenics, sold to women via before-and-after photos, until the FDA banned them after strokes and deaths. Fen-phen followed the same arc: a “miracle drug” that was later linked to heart valve damage. The wellness industry moves faster than the evidence, and women, who have been told their entire lives that their bodies require constant management, are the readiest market.
The entry point this time is a questionnaire, an approval in 20 minutes, and a vial shipped to your doorstep without a conversation that would qualify as medical care by any standard I was trained to apply. During the years when branded semaglutide was on the FDA shortage list, compounding pharmacies were legally permitted to manufacture copies of the drug. Telehealth platforms multiplied to meet a demand that the formal medical system had priced out of reach for those who needed it. By September 2025, the FDA had issued more than 55 warning letters to these platforms for misleading advertising, and spent the following year slowly closing the regulatory pathways that made it all possible. The harm those years produced is still arriving in exam rooms like mine.
Poison control centers have seen a nearly 1,500 percent increase in calls related to GLP-1 overdose and adverse effects since 2019.
Poison control centers have seen a nearly 1,500 percent increase in calls related to GLP-1 overdose and adverse effects since 2019. Between January and April of 2025 alone, they managed more than 3,600 cases. That number exists in medical journals and pharmacovigilance databases. It is not in your group text because the platforms that placed the vial in your mailbox had no reason to ensure that information reached you.
Branded GLP-1 medications come in pre-filled pens with built-in titration schedules, a deliberate design that walks you up to the right dose slowly, because these drugs accumulate in your system, and starting too high causes real harm. Compounded versions arrive as multi-dose vials with a syringe, and the conversion between vial labeling and syringe markings is not intuitive. One 45-year-old woman described in a clinical toxicology case series injected nearly 10 times her intended starting dose on her very first try — not through carelessness, but because the system that prescribed to her assumed knowledge she had never been given.
My friend had a similar story. She had no framework for any of this. The drug she received came with a vial, a syringe, and an assumption that she would figure out the rest. Within hours of that first dose, she was vomiting, unable to keep anything down. The platform that had approved her prescription in 20 minutes had no protocol for what to do next. She called poison control.
My friend went to the doctor and found out her liver enzymes were elevated, a signal that her liver was struggling to process what had entered her system. It required months of monitoring to ensure it didn't worsen. She would sit in the waiting room and think about the form she had filled out, the friend who had sent her the link, the provider whose credentials she still could not name with certainty, the vial that arrived like something she’d ordered from a catalog. Her levels eventually returned to normal — but it took months.
The center of gravity of the GLP-1 story is women in midlife, and it has been hiding in plain sight. Research from the RAND American Life Panel found that women between 50 and 64 are the highest users of GLP-1 drugs in the United States, with one in five reporting current or past use. Women between 30 and 49 are more than twice as likely as men of the same age to report using them. Across years of national poison center data, roughly 70 to 73 percent of GLP-1 exposure cases have involved women.
That woman is still asking herself what she missed. And I want to tell her, as her physician and as someone who has received every one of the same messages she has about what a body like hers is supposed to look like, that she missed nothing. She was failed by a system that used her discomfort as a revenue stream and called it care. The responsibility doesn't belong to her. It belongs to an industry that promoted a solution, handed her a syringe, never taught her how to use it, and is still, right now, marketing that “solution” to other vulnerable women.
